Rays of Belief IPO Review: Revenue Jumped 124%, EBITDA Margin at 14.59% & Full Analysis

Rays of Belief Limited, operating under the established brand 'Mom’s Belief', is a unique social enterprise dedicated to addressing neuro-developmental disorders through specialised clinical interventions and learning centres.

By operating an integrated model of physical clinics and digital therapeutic support, the company provides critical care for children and young adults globally.

Marking its transition to a publicly traded entity, the Rays of Belief IPO opens for bidding on September 1, 2026, and concludes its public subscription phase on September 3, 2026.

The firm aims to raise up to ₹125.00 crores via a completely fresh issue of 52,30,000 equity shares to fund domestic expansion and support its US-based clinical subsidiaries. Retail investors must subscribe to at least 62 equity shares per lot, based on the finalized IPO price band of ₹227 to ₹239 per share.

Readers will find essential details regarding the Rays of Belief IPO in this report, including the current grey market premium (GMP), subscription progress, key allotment dates, the specified price band, and an evaluation of the company.

Brief of Rays of Belief IPO Details

• Price Band: ₹227 – ₹239 per share
• IPO Open / Close Dates: 1 September 2026 / 3 September 2026
• Lot Size: 62 shares (Minimum retail investment: ₹14,818)
• Issue Size: 52,30,000 shares / Up to ₹125.00 crores
• Fresh Issue / OFS: Fresh Issue of ₹125.00 crores / OFS of ₹0.00 crores
• Registrar: KFin Technologies Ltd.
• Listing Exchange: BSE, NSE

IPO Reservation

• Face value: ₹10 per share
• Anchor offer: Up to 60% of the QIB Portion
• QIB-shares: Not less than 75% of the Issue size
• NIIs-Shares offered: Not more than 15% of the Issue
• RIIs- Shares offered: Not more than 10% of the Issue

What is the GMP of the Rays of Belief IPO Today?

You can track the ongoing grey market premium (GMP) updates for these listings via our hub page. 

Please be aware that these figures change daily based on demand and function purely as an unofficial indicator not regularised by SEBI, NSE, or BSE. 

What Are The Important IPO Dates & Allotment Schedule for the Rays of Belief offering?

• IPO Open & Close Date: 1 September 2026 to 3 September 2026
• Basis of Allotment Date: 4 September 2026
• Refund Initiation Date: 7 September 2026
• Credit of Shares: 7 September 2026
• Listing Date: 8 September 2026

What Are The Primary Objectives of Rays of Belief IPO?

The administrative leadership of Rays of Belief intends to deploy the net capital from this fresh share issuance for the specific core purposes detailed below:

• Domestic Expansion: An allocation of ₹41.36 crores is earmarked for establishing 319 new therapy and learning centres across Tier-2 and Tier-3 Indian cities, covering fit-outs and clinical inventory.
• Operational Contingencies: Approximately ₹14.44 crores will be directed towards meeting existing lease rental commitments for Indian centres, safeguarding operational continuity.
• Subsidiary Support: The firm will invest ₹10.13 crores into its US subsidiary to cover lease and license payments for its recently acquired international clinical centres.

How is The Financial Performance of Rays of Belief?

Presented below is an abstract of the historical financial records for Rays of Belief, denominated in Crores of Rupees.

Source: RHP of Rays of Belief Limited

Financial Observations

Total Income

The company registered exceptional upward momentum in its revenue base due to strategic international expansion.

• Total income scaled massively from ₹30.76 crores in FY24 to ₹82.06 crores in FY26.
• The strategic acquisition of US-based clinics contributed over 41% to the consolidated FY26 revenue.
• High-margin export services for clinical innovation and R&D further accelerated this top-line scale-up.

Profit After Tax

Net profitability demonstrated a solid underlying operational turnaround despite apparent numerical fluctuations.

• PAT surged to ₹5.88 crores in FY25 before normalising at ₹4.96 crores in FY26.
• The FY25 bottom line was heavily inflated by a one-time, non-cash deferred tax credit of ₹5.53 crores.
• Stripping away this tax anomaly, the core operating profit expanded exponentially due to US clinic integrations.

EBITDA

Core operational earnings advanced significantly, reflecting the firm's improved ability to absorb fixed clinical overheads.

• EBITDA jumped aggressively from ₹1.49 crores in FY24 to ₹11.91 crores in FY26.
• The EBITDA margin widened to a competitive 14.59% during the most recent fiscal period.
• A strategic shift from unprofitable "Network Centres" to direct "Company Learning Centres" protected these margins.

Total Borrowing

The business maintained an exceptionally conservative and de-risked capital structure during its rapid expansion phase.

• Total borrowings stood at a mere ₹3.61 crores in FY26, down from ₹4.36 crores in FY25.
• These funds consist entirely of unsecured inter-corporate borrowings from related parties at a reducing interest rate.
• The resulting debt-to-equity ratio of 0.12x leaves the company highly insulated from interest rate shocks.

Assets

The overall resource base of the company widened to reflect its asset-light leasing model and recent US acquisitions.

• Total assets grew dramatically from ₹12.89 crores in FY24 to ₹50.89 crores in FY26.
• This build-up includes the recognition of ₹4.99 crores in Goodwill from the strategic buyout of US clinical operations.
• Leased premises accounted for ₹5.37 crores in Right-of-Use (ROU) assets, highlighting minimal upfront capital expenditure.

What Are the P/E ratio and Peer Comparison of Rays of Belief Limited?

Rays of Belief's P/E ratio of 74.45x is determined by measuring the highest offering price of ₹239 against its recorded FY26 earnings per share of ₹3.21. 

Analysis:

According to the Red Herring Prospectus, there are no listed companies in India whose business portfolio and scale of operations within the behavioural health and neurodevelopmental space are directly comparable to Rays of Belief Limited.

Consequently, a direct domestic peer valuation matrix cannot be established. 

At the upper price band of ₹239, the firm enters the primary market demanding an implied P/E multiple of approximately 74.45x.

While operating on a consolidated revenue base of ₹81.66 crores, the company delivers a respectable Return on Net Worth (RoNW) of 16.09%.

This premium valuation multiple reflects the market's high growth expectations for a first-mover social enterprise capitalising on the rapidly formalising global behavioural health market.

What is the Industry Outlook of Rays of Belief Limited?

Growth potential

• The global and domestic awareness surrounding neurodevelopmental disorders (NDD) and behavioural health is rising exponentially, establishing a vast, untapped addressable market.
• Early intervention mandates and growing insurance coverage for paediatric therapies ensure a steady, recurring pipeline of clinical volume for established providers.
• Cross-border clinical services—where standard R&D and operational support are exported to higher-paying international markets—offer significant high-margin revenue potential.

Market trends

• The behavioural healthcare space remains highly fragmented; scalable success depends on establishing trusted brand equity and clinical standardisation across multiple fragmented clinics.
• There is a clear industry transition towards asset-light, leased expansion models rather than heavy real-estate ownership, allowing providers to rapidly establish footholds in underserved regions.
• Attracting and retaining licensed therapists and clinical professionals remains the primary operational bottleneck, driving up fixed administrative overheads and employee costs.

What Are The Strengths and Risks of Rays of Belief IPO ?

Strengths:

• Global Expansion: The strategic acquisition of US-based clinics transformed the revenue base, contributing over 41% to the consolidated FY26 revenue and driving high-margin export growth.
• Low Debt Profile: The company maintains an exceptionally conservative capital structure, operating with a minimal debt-to-equity ratio of 0.12x in FY26.
• Margin Expansion: A strategic shift towards direct "Company Learning Centres" enabled better absorption of fixed overheads, tripling the EBITDA margin to 14.59% in FY26.

Risks:

• Regulatory Requirement: The company is listing under SEBI Regulation 6(2), meaning the IPO will fail if institutional demand doesn't meet the mandatory 75% minimum threshold for the QIB portion.
• Lease Vulnerability: The asset-light expansion model relies heavily on leased properties, exposing the firm to potential lease non-renewals or unexpected rental escalations.
• Earnings Distortion: Historical reported profits were inflated by a one-time non-cash deferred tax credit of ₹5.53 crores in FY25, slightly distorting the visible net profitability trend.

Key Considerations for Investors

• Valuation Premium: At the upper band, the company demands an implied P/E of 74.45x. With no listed domestic peers, investors must evaluate this premium against its first-mover advantage in the NDD space.
• Regulatory Listing Constraints: Issued under SEBI’s 6(2) "unprofitable company" route, the IPO requires a massive 75% QIB subscription to succeed, leaving only 10% for retail investors.
• US Market Reliance: The financial turnaround in FY26 was heavily driven by the integration of US therapy centres, leaving the firm exposed to international healthcare regulations and forex volatility.
• Operating Leverage: The firm’s asset-light model yields a highly conservative debt-to-equity ratio of 0.12x, while delivering a solid 16.09% Return on Net Worth (RoNW).

IPO Related Resources

1. Upcoming & Live IPOs in India

2. IPO Allotment Status – How to Check Allotment Status of IPO Shares

3. Latest IPO Subscription Status Today

4. IPO Market Analytics

5. July 2026 IPO Subscription Review: 32 IPOs Data, Demand Patterns & Key Trends

6. July 2026 IPO Review: 33 IPOs, ₹21140.52 Cr Raised & 56.37x Average Subscription

Key Takeaways

• IPO Price Band: ₹227 to ₹239 per equity share
• Lot Size: 62 shares (Minimum retail application of ₹14,818)
• Allotment Date: Allotment on 4 September 2026
• Listing Date: Listing on BSE and NSE on 8 September 2026

FAQs on Rays of Belief IPO

What is Rays of Belief IPO GMP today?

You can find the latest GMP updates for this issue on our dedicated GMP hub page, as unofficial premium indicators change daily based on market sentiment.

What is the Rays of Belief IPO price band?

The price band has been fixed at ₹227 to ₹239 per equity share.

What is the Rays of Belief IPO allotment date?

The basis of allotment is scheduled to be finalised on 4 September 2026.

How to check Rays of Belief IPO allotment status?

Once finalised, investors can verify their allotment status by visiting the official portal of the registrar, KFin Technologies Ltd., and submitting their PAN or application details.

What is the Rays of Belief IPO listing date?

The equity shares are proposed to be listed on the BSE, NSE platform on 8 September 2026.

Investment Perspective on Rays of Belief IPO

Rays of Belief offers a compelling high-growth niche as a leading neurodevelopmental care provider. While its rapid US clinic consolidation and 63% three-year revenue CAGR prove market scalability, critical risks loom.

The company struggles with persistent negative operating cash flows (-₹19.41 million in FY26) and a concerning spike in trade receivables to ₹180.88 million, largely tied to related parties. Long-term investors must carefully weigh this aggressive top-line expansion against underlying collection, liquidity, and operational integration risks before committing hard capital.
Disclaimer: This information is intended for educational purposes only and does not constitute formal financial advice. Investors should consult a SEBI-registered investment advisor before making any financial commitments.